Repligen (RGEN) News Today

Sumitomo Mitsui Trust Holdings Inc. lowered its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 9.0% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 97,513 shares of the biotechnology company

Assenagon Asset Management S.A. grew its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 937.8% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 30,189 shares of the biotechnology company's stock after purchasing

Repligen (NASDAQ:RGEN) Stock Price Up 4.2%

Artemis Investment Management LLP reduced its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 47.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 87,809 shares of the biotechnology company's

Janus Henderson Group PLC cut its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 93.1% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,968 shares of the biotechnology company's stock after selling 53,315 shares during the

Benchmark reaffirmed a "hold" rating on shares of Repligen in a report on Monday.

Swedbank AB acquired a new stake in Repligen Co. (NASDAQ:RGEN - Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 30,000 shares of the biotechnology company's stock, valued at approximately $5,518,000. Swedba

Comerica Bank trimmed its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 3.2% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 123,021 shares of the biotechnology company's stock after selling 4,090 shares during the per

Repligen Co. (NASDAQ:RGEN - Free Report) - Equities research analysts at William Blair lifted their Q4 2024 EPS estimates for shares of Repligen in a report issued on Tuesday, July 30th. William Blair analyst M. Larew now forecasts that the biotechnology company will post earnings per share of $0

JPMorgan Chase & Co. raised their target price on shares of Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a research report on Wednesday.

UBS Group decreased their price target on shares of Repligen from $205.00 to $185.00 and set a "buy" rating for the company in a research report on Wednesday.

Royal Bank of Canada reaffirmed an "outperform" rating and set a $190.00 target price on shares of Repligen in a report on Wednesday.

Repligen (NASDAQ:RGEN - Get Free Report) announced its quarterly earnings data on Tuesday. The biotechnology company reported $0.33 earnings per share for the quarter, hitting the consensus estimate of $0.33. The company had revenue of $154.07 million during the quarter, compared to analyst estimates of $154.11 million. Repligen had a net margin of 2.44% and a return on equity of 3.95%. The firm's revenue for the quarter was down 3.2% compared to the same quarter last year. During the same period last year, the business earned $0.53 EPS.

Repligen (NASDAQ:RGEN) Shares Gap Up to $138.00

Stephens reiterated an "overweight" rating and set a $170.00 price target on shares of Repligen in a research report on Tuesday.

Repligen (NASDAQ:RGEN) updated its FY 2024 earnings guidance. The company provided EPS guidance of 1.420-1.490 for the period, compared to the consensus estimate of 1.450. The company also issued revenue guidance of $620.0 millionillion-$635.0 millionillion, compared to the consensus estimate of $636.6 millionillion.

Price T Rowe Associates Inc. MD lessened its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 11.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,568,316 shares of the biotechnology company's stock aft

Repligen (NASDAQ:RGEN) Shares Up 7.3%

Bessemer Group Inc. decreased its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 8.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 305,136 shares of the biotechnology company's stock after sell

Repligen (NASDAQ:RGEN) will be releasing earnings before the market opens on Tuesday, July 30, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=332912)

Westfield Capital Management Co. LP lessened its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 20.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 235,310 shares of the biotechnology company's s

Repligen Co. (NASDAQ:RGEN - Get Free Report) has received an average recommendation of "Moderate Buy" from the ten research firms that are presently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to

Repligen Co. (NASDAQ:RGEN - Free Report) - Equities researchers at Leerink Partnrs issued their FY2026 EPS estimates for shares of Repligen in a research report issued on Thursday, July 18th. Leerink Partnrs analyst P. Souda anticipates that the biotechnology company will post earnings per share

BNP PARIBAS ASSET MANAGEMENT Holding S.A. lessened its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 11.5% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 292,740 shares of the biotechnology company's stock after selli

Swiss National Bank reduced its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 4.1% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 158,800 shares of the biotechnology company's stock after selling 6